In the U.S., idiopathic pulmonary fibrosis (IPF) mortality rates decreased from 2004 to 2017, a new study shows. The data suggests the decline might be partly explained by a decline in smoking, but further research is needed to better understand the factors contributing to this trend. The study, “Mortality Trends…
News
Galecto‘s investigational compound GB0139, now in an enrolling clinical trial, has been designated an orphan drug by the U.S. Food and Drug Administration and the European Medicines Agency (EMA) as a potential treatment of idiopathic pulmonary fibrosis (IPF). GB0139 (formerly TD139) is an inhaled small molecule inhibitor of…
AbbVie will assume development of Morphic Therapeutic‘s alpha v beta 6 (αvβ6) integrin inhibitors as potential treatments for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, exercising a licensing option under an earlier research partnership between the companies. Integrins control a wide variety of cellular processes, including…
Raremark, an online rare disease patient community, has launched a digital platform called Xperiome, aimed at streamlining the search for new medicines for rare disorders and incorporating more patient input into research. The goal is to help the pharmaceutical industry deliver innovative new therapies faster and smarter, the…
Four years of monitoring clinical use of Ofev (nintedanib) by people with idiopathic pulmonary fibrosis (IPF) has found no new safety concerns, a database study found. Treatment safety and tolerability were consistent with findings reported in pivotal trials, with non-severe diarrhea continuing to be the most common side effect noted,…
People with idiopathic pulmonary fibrosis (IPF) who are treated with either Ofev (nintedanib) or Esbriet (pirfenidone) report similar satisfaction with their medications, a new study suggests. The study, “Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study,”…
NXP004, Nuformix’s potential anti-fibrotic treatment for idiopathic pulmonary fibrosis (IPF), led to a dose-dependent reduction in the production and deposition of proteins that are known key drivers of fibrosis (tissue scarring) and IPF progression, a preclinical study shows. Although these are preliminary findings in a tissue study,…
Adelmidrol therapy reduced markers for inflammation and oxidative stress, as well as tissue damage and collagen deposits, in the lungs of mice with pulmonary fibrosis (PF), a study has found. The findings support further investigation of adelmidrol as a…
The EveryLife Foundation for Rare Diseases has launched a scholarship fund in the U.S. to support individuals with rare disorders who are pursuing personal goals through training and education. The initial phase of the five-year, $1-million #RAREis Scholarship Fund will include 32 scholarships — each totaling $5,000 —…
A gene therapy that lengthens the life of lung cells can halt scarring and help sustain lung regeneration in a mouse model of age-related pulmonary fibrosis, a new study shows. The study, “Telomerase treatment prevents lung profibrotic pathologies associated with physiological aging,” was published in the Journal…
